Abstract
Get full access to this article
View all access options for this article.
References
1.
Philippidis
A
. Bluebird Bio Eliminating 30% of Workforce in Restructuring. Genetic Engineering & Biotechnology News, April 5, 2022. www.genengnews.com/topics/genome-editing/gene-therapy/bluebird-bio-eliminating-30-of-workforce-in-restructuring/ (last accessed
April 12 , 2022
).
2.
Bluebird Bio. Form 10-K Annual Report for 2021. Filed March 4, 2022, with the U.S. Securities and Exchange Commission. https://investor.bluebirdbio.com/static-files/b5cf7b5a-ff26-4ebc-8d9e-9c99d9701b7a (last accessed
April 12 , 2022
).
3.
Bluebird Bio. Bluebird bio initiates restructuring to reduce operating expenses and advance near-term opportunities to bring potentially curative gene therapies to patients in the US. April 5, 2022. https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-initiates-restructuring-reduce-operating-expenses (last accessed
April 12 , 2022
).
4.Evozyne . Evozyne announces multi-target research collaboration and license agreement with takeda to develop next-generation gene therapies. April 5, 2022. https://www.evozyne.com/news/evozyne-announces-multi-target-research-collaboration-and-license-agreement-with-takeda-to-develop-next-generation-gene/ (last accessed
April 12 , 2022
).
5.
FUJIFILM Corp. Fujifilm to ACQUIRE Shenandoah Biotechnology, leading manufacturer of recombinant proteins. March 22, 2022. https://www.irvinesci.com/blog/fujifilm-to-acquire-shenandoah-biotechnology-leading-manufacturer-of-recombinant-proteins.html# (last accessed
April 12 , 2022
).
6.
Alliance for Regenerative Medicine. 2021 Annual Report. March 31, 2022. https://alliancerm.org/press-release/cell-and-gene-therapies-poised-to-disrupt-health-care-status-quo-with-wave-of-new-treatments/ (last accessed
April 12 , 2022
).
7.
Alliance for Regenerative Medicine. Cell and gene therapies poised to disrupt health care status quo with wave of new treatments. March 31, 2022. https://alliancerm.org/press-release/cell-and-gene-therapies-poised-to-disrupt-health-care-status-quo-with-wave-of-new-treatments/ (last accessed
April 12 , 2022
).
8.
Bayer. Bayer set to drive breakthrough innovations in the Life Sciences. April 1, 2022. https://media.bayer.com/baynews/baynews.nsf/id/Bayer-set-to-drive-breakthrough-innovations-in-the-Life-Sciences?Open&parent=news-overview-category-search-en&ccm=020 (last accessed
April 14 , 2022
).
9.Institute for Clinical and Economic Review (ICER) . Betibeglogene autotemcel for beta thalassemia: Effectiveness and value. April 13, 2022. https://icer.org/wp-content/uploads/2021/11/ICER_Beta-Thalassemia_Draft-Report_041322.pdf (last accessed
April 14 , 2022
).
10.
GenSight Biologics. GenSight Biologics granted six-month extension in LUMEVOQ® European Regulatory Review. April 14, 2022. https://www.gensight-biologics.com/2022/04/14/gensight-biologics-granted-six-month-extension-in-lumevoq-european-regulatory-review/ (last accessed
April 14 , 2022
).